GlaxoSmithKline plc (NYSE:GSK) announced a quarterly dividend on Thursday, November 1st, NASDAQ reports. Investors of record on Friday, November 16th will be given a dividend of 0.486 per share by the pharmaceutical company on Thursday, January 10th. This represents a $1.94 annualized dividend and a dividend yield of 4.71%. The ex-dividend date is Thursday, November 15th. This is an increase from GlaxoSmithKline’s previous quarterly dividend of $0.46.

GlaxoSmithKline has decreased its dividend by an average of 8.9% per year over the last three years. GlaxoSmithKline has a dividend payout ratio of 66.0% meaning its dividend is sufficiently covered by earnings. Research analysts expect GlaxoSmithKline to earn $3.05 per share next year, which means the company should continue to be able to cover its $1.94 annual dividend with an expected future payout ratio of 63.6%.

NYSE GSK opened at $41.30 on Friday. The company has a debt-to-equity ratio of 6.66, a current ratio of 0.95 and a quick ratio of 0.63. GlaxoSmithKline has a twelve month low of $34.52 and a twelve month high of $42.36. The stock has a market capitalization of $101.21 billion, a P/E ratio of 14.34, a P/E/G ratio of 2.74 and a beta of 0.80.

GSK has been the subject of several research reports. TheStreet upgraded shares of GlaxoSmithKline from a “c” rating to a “b” rating in a research note on Monday, August 6th. Goldman Sachs Group reiterated a “buy” rating on shares of GlaxoSmithKline in a research note on Wednesday, October 10th. Shore Capital upgraded shares of GlaxoSmithKline from a “hold” rating to a “buy” rating in a research note on Friday, July 27th. Argus increased their price target on shares of GlaxoSmithKline from $45.00 to $47.00 and gave the stock a “buy” rating in a research report on Monday, August 20th. Finally, Zacks Investment Research raised shares of GlaxoSmithKline from a “hold” rating to a “buy” rating and set a $45.00 price target for the company in a research report on Tuesday, September 25th. Eleven analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus target price of $41.57.

COPYRIGHT VIOLATION NOTICE: This report was first reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this report on another publication, it was illegally stolen and republished in violation of US & international copyright and trademark legislation. The original version of this report can be accessed at

About GlaxoSmithKline

GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of vaccines, over-the-counter medicines, and health-related consumer products worldwide. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, dermatology, rare diseases, immuno-inflammation, and HIV, as well as vaccines.

Read More: Earnings Reports

Dividend History for GlaxoSmithKline (NYSE:GSK)

Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with's FREE daily email newsletter.